Désogestrel ( DrugBank: Désogestrel )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 230 | Alveolar hypoventilation syndrome | 1 |
230. Alveolar hypoventilation syndrome
Clinical trials : 8 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 18 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-000989-35-FR (EUCTR) | 06/05/2011 | N/A | N/A - RESPIRONDINE | MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Cerazette Product Name: Cerazette INN or Proposed INN: Désogestrel | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | NA | Female: yes Male: no | Phase 2 | France |